GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $1.95 $2.64 Friday, 19th Apr 2024 CHRS stock ended at $2.07. This is 3.50% more than the trading day before Thursday, 18th Apr 2024. During the day the stock fluctuated 7.18% from a day low at $1.95 to a day high of $2.09.
90 days $1.93 $2.97
52 weeks $1.44 $8.33

Historical Coherus BioSciences prices

Date Open High Low Close Volume
2024-02-07 $2.29 $2.34 $2.22 $2.32 5 219 296
2024-02-06 $2.01 $2.33 $1.97 $2.32 4 164 014
2024-02-05 $1.99 $2.08 $1.93 $2.02 3 489 931
2024-02-02 $2.03 $2.10 $1.93 $2.06 3 954 988
2024-02-01 $2.15 $2.21 $2.08 $2.09 3 426 870
2024-01-31 $2.28 $2.34 $2.15 $2.15 4 225 198
2024-01-30 $2.28 $2.33 $2.18 $2.31 6 765 232
2024-01-29 $2.31 $2.38 $2.24 $2.30 4 137 379
2024-01-26 $2.36 $2.40 $2.31 $2.34 1 619 578
2024-01-25 $2.33 $2.41 $2.23 $2.37 3 552 915
2024-01-24 $2.39 $2.50 $2.30 $2.30 6 284 745
2024-01-23 $2.60 $2.63 $2.33 $2.40 6 760 496
2024-01-22 $2.73 $2.97 $2.46 $2.58 22 393 067
2024-01-19 $2.52 $2.56 $2.36 $2.44 6 892 402
2024-01-18 $2.52 $2.53 $2.33 $2.40 2 771 994
2024-01-17 $2.32 $2.51 $2.30 $2.46 5 928 728
2024-01-16 $2.52 $2.53 $2.33 $2.35 4 546 927
2024-01-12 $2.59 $2.73 $2.53 $2.57 3 547 863
2024-01-11 $2.80 $2.81 $2.60 $2.62 5 530 174
2024-01-10 $2.98 $2.98 $2.71 $2.86 11 732 443
2024-01-09 $3.06 $3.13 $2.91 $2.98 4 663 868
2024-01-08 $2.87 $3.10 $2.74 $3.08 5 144 585
2024-01-05 $2.89 $3.02 $2.74 $2.87 4 881 520
2024-01-04 $3.05 $3.16 $2.83 $2.92 6 876 823
2024-01-03 $3.10 $3.22 $2.93 $3.02 8 770 121
Click to get the best stock tips daily for free!

About Coherus BioSciences

Coherus BioSciences Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ... CHRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT